Ibogaine & noribogaine · dated record
A milestone view of regulatory, clinical, corporate, policy, and market events relevant to ibogaine and noribogaine through 2026.
How to read the record
The timeline puts discrete events in sequence and identifies the kind of source behind each one. It does not treat a filing, a study, or a company announcement as an investment conclusion.
Ibogaine was isolated from Tabernanthe iboga in the early twentieth century. Its chemical history is commonly summarized in the ibogaine reference record, which also notes its later use in research and its legal restrictions in multiple jurisdictions.
Ibogaine became a Schedule I controlled substance in the United States. The current federal scheduling framework is maintained in the Drug Enforcement Administration schedules; scheduling status is distinct from clinical research authorization.
U.S. federal discussion of ibogaine included public scientific review and research-oriented consideration. These early activities are best understood as process milestones rather than evidence of marketing authorization or established clinical benefit.
Clinical & regulatory pathway
Noribogaine, a metabolite of ibogaine, became a distinct development focus as companies explored compounds and formulations intended to separate program design from the historical use of ibogaine itself. Publicly listed research records can be located through the ClinicalTrials.gov study registry, although a registry entry does not establish results or approval.
In the 2010s, DemeRx and related program communications placed noribogaine filings and early-stage development into the corporate record. Such filings, authorizations, and Phase I references are regulatory-development markers; they should not be read as proof of efficacy, safety, or a future commercial outcome.
For a narrower explanation of how the site organizes research and sector materials, the research mapping approach provides the relevant companion context.
A practical evidence sequence
A dated sector view works best when regulatory, peer-reviewed, corporate, and market records are kept separate. One category can change without resolving the others.
DemeRx disclosed work around noribogaine and related regulatory submissions. A company statement can establish that an announcement was made, but it remains a corporate source and should be read alongside registries, filings, and later publications where available.
Published discussion of ibogaine has repeatedly identified cardiac-risk considerations, including QT-interval concerns. The FDA’s explanation of QT-related rhythm risk is general drug-safety context, not an ibogaine-specific determination.
Later milestones may include financings, partnerships, patent grants or disputes, registered trial updates, and jurisdiction-specific policy changes. A clean timeline records the date, entity, source type, and what the source actually says before drawing any broader comparison.
Evidence discipline
“A milestone is a documented event. It is not, by itself, a clinical conclusion or an investment thesis.”
When reviewing claims tied to ibogaine or noribogaine, distinguish peer-reviewed results from company press releases and regulatory process from approval. The independence and accuracy principles explain the standards used to preserve that distinction across this resource.
Country-level status also requires care: laws, enforcement, research permissions, and health-policy positions may differ within the same broad subject area. The World Health Organization’s substance-use resources provide broader public-health context without determining the status of any specific ibogaine program.
Timeline notes
It records dated regulatory, research, corporate, policy, financing, and intellectual-property milestones specific to ibogaine and noribogaine. Each entry identifies its source type and avoids investment recommendations.
No. A regulatory designation, filing, or authorization is a process milestone. It does not by itself establish safety, effectiveness, approval, or commercial outcome.
They are related but not interchangeable in a development record. A timeline should identify the named compound, formulation, program, or study rather than treating all sector activity as the same event.
They document what an organization announced on a given date. Their claims require clear labelling and, where relevant, comparison with regulatory records, trial registries, peer-reviewed papers, or public filings.
Keep the sequence intact
The value of a sector timeline is traceability: what happened, when it happened, and what record supports it.